Currently, several clinical trials are underway with CAR T cells targeting mesothelin (NCT03638193, NCT03323944), CEA (NCT03818165, NCT04037241, NCT02850536) and claudin 18.2 (NCT04404595, NCT04581473) and the results should unravel whether such treatments can be of therapeutic value in patients with pancreatic cancer. Here, MSLN is linked to pancreatic neoplasm.